TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB43250

Peptide_Name

P6

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

CancerPPD 2.0 dbACP

Sequence_Type

standard

Has_Modification No

Description A 20-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0 and dbACP, with an available 3D structural model.

Sequence

WYIRKIRRFFKWLKKKLKKK

FASTA

>TPDB43250|Anticancer|length=20
WYIRKIRRFFKWLKKKLKKK

Formula C139H225N39O22

Absent Amino Acids ANDCEQGHMPSTV

Common Amino Acids K

Mass 2794.56

PI 12.20

Basic Residues 11

Acidic Residues 0

Hydrophobic Residues 9

Net Charge +11

Boman Index 1.71

Hydrophobicity -1.280

Aliphatic Index 78.00

Half Life

Mammalian: 2.8 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 12490

Absorbance 280nm 446.94

Polar Residues 1

number

0

A

3

R

0

N

0

D

0

C

0

E

0

Q

0

G

0

H

2

I

2

L

8

K

0

M

2

F

0

P

0

S

0

T

2

W

1

Y

0

V

Amino Acid Distribution

A: 0 R: 3 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 2 L: 2 K: 8 M: 0 F: 2 P: 0 S: 0 T: 0 W: 2 Y: 1 V: 0

Length

20

Formula

C139H225N39O22

Mass

2794.56

PI

12.20

Net Charge

+11

Boman Index

1.71

Hydrophobicity

-1.280

C_terminal_Modification

Free

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antitumor

Origin

Arca inflata

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 4.43 ± 0.15 µg/mL

Detail Source Activity Anticancer

Activity Measurement 4.43

Target

Cancer Type Colorectal Cancer

Cell Line HT-29

Tissue Affected Colon

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2022

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 2.14 ± 0.28 µg/mL

Detail Source Activity Anticancer

Activity Measurement 2.14

Target

Cancer Type Colorectal Cancer

Cell Line DLD-1

Tissue Affected Colon

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2022

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 10.88 ± 0.72 µg/mL

Detail Source Activity Anticancer

Activity Measurement 10.88

Target

Cancer Type Colorectal Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2022

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 >27 µg/mL

Detail Source Activity Anticancer

Activity Measurement 27 µg/mL

Target

Cancer Type Colon Cancer

Cell Line SW-620

Tissue Affected Colon

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2022

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 >150 µg/mL

Detail Source Activity Anticancer

Activity Measurement 150 µg/mL

Target

Cancer Type Colorectal Cancer

Cell Line L02

Tissue Affected Colon

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2022